Cargando…

Interleukin-6 receptor inhibition with tocilizumab in various renal involvements associated with multicentric Castleman's disease: a report of three cases

Multicentric Castleman's disease (MCD) is an inflammatory lymphoproliferative disorder characterized by polyclonal hypergammopathy and dysregulated overproduction of interleukin-6 (IL-6). A variety of renal involvements infrequently arise in patients with MCD. However, there is no established t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Komaba, Hirotaka, Nakazawa, Takashi, Yamaguchi, Yutaka, Kumagai, Shunichi, Fukagawa, Masafumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2008
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477882/ https://www.ncbi.nlm.nih.gov/pubmed/28656995 http://dx.doi.org/10.1093/ndtplus/sfn157

Ejemplares similares

Sustained remission of Multicentric Castleman Disease in children treated with tocilizumab
por: Galeotti, C, et al.
Publicado: (2011)

Aseptic Meningitis-retention Syndrome Associated with Tocilizumab in a Patient with Idiopathic Multicentric Castleman Disease
por: Arakawa, Akira, et al.
Publicado: (2021)

A Case of Multicentric Castleman's Disease Having Lung Lesion Successfully Treated with Humanized Anti-interleukin-6 Receptor Antibody, Tocilizumab
por: Higuchi, Tomoaki, et al.
Publicado: (2010)

Idiopathic multicentric Castleman disease preceded by cutaneous plasmacytosis successfully treated by tocilizumab
por: Aita, Tetsuro, et al.
Publicado: (2020)

Psoas and Mediastinal Abscesses during Intravenous Tocilizumab Treatment in Multicentric Castleman Disease
por: Togitani, Kazuto, et al.
Publicado: (2022)

Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases
por: Nagao, Azusa, et al.
Publicado: (2014)

Treatment of multicentric Castleman disease through combination of tocilizumab, lenalidomide and glucocorticoids: Case report
por: Cai, Sisi, et al.
Publicado: (2019)

Successful treatment with tocilizumab for refractory anemia and slowly progressive renal glomerulosclerosis in multicentric Castleman disease: A case report
por: Sugawara, Eri, et al.
Publicado: (2022)

Pathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention
por: Goto, Shunsuke, et al.
Publicado: (2008)

Relapse of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine
por: Komaba, Hirotaka, et al.
Publicado: (2021)

Idiopathic multicentric Castleman disease with pulmonary and cutaneous lesions treated with tocilizumab: A case report
por: Han, Ping-Yang, et al.
Publicado: (2020)

Idiopathic Multicentric Castleman Disease with Autoimmune Hemolytic Anemia and Production of Anti-drug Antibody against Tocilizumab
por: Tabata, Sakiko, et al.
Publicado: (2019)

Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder
por: Goto, Shunsuke, et al.
Publicado: (2013)

Membranous nephropathy associated with multicentric Castleman’s disease that was successfully treated with tocilizumab: a case report and review of the literature
por: Saiki, Ryosuke, et al.
Publicado: (2021)

Multicentric Castleman's disease: Report of three cases
por: Guazzaroni, M., et al.
Publicado: (2018)

Case report: Importance of early and continuous tocilizumab therapy in nephrotic syndrome associated with idiopathic multicentric Castleman disease: A case series
por: Kojima, Daiki, et al.
Publicado: (2023)

Tocilizumab for refractory Castleman’s disease with paraneoplastic pemphigus and Behçet’s disease
por: Vargas, Ana Beatriz, et al.
Publicado: (2012)

Refractory Uveitis in Patient with Castleman Disease Successfully Treated with Tocilizumab
por: Oshitari, Toshiyuki, et al.
Publicado: (2012)

A Retrospective Study on Erythropoiesis Stimulating Agent Dose Reducing Potential of an Anti‐Platelet Activation Membrane Dialyzer in Hemodialysis Patients
por: Kakuta, Takatoshi, et al.
Publicado: (2018)

Acute cardiac overload does not induce cardiac or skeletal expression of fibroblast growth factor 23 in rats
por: Fajol, Abul, et al.
Publicado: (2021)

Tocilizumab-effective multicentric Castleman's disease with infiltration of eosinophil and IgG(4)-positive plasma cells: A case report
por: Katsumata, Yusuke, et al.
Publicado: (2018)

HIV-associated multicentric Castleman's disease
por: Naime, Fauzia de Fátima, et al.
Publicado: (2012)

Multicentric Castleman disease and the evolution of the concept
por: Zhou, Ting, et al.
Publicado: (2021)

Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports
por: Ferrero, Simone, et al.
Publicado: (2021)

Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism
por: Tanaka, Motoko, et al.
Publicado: (2008)

The Pituitary Is a Candidate Organ That Modulates Circulating Klotho Levels
por: Sato, Tetsuhiko, et al.
Publicado: (2018)

Multicentric Castleman's disease: a case report
por: Menezes, Brian F, et al.
Publicado: (2007)

Multicentric Castleman disease with TAFRO syndrome and Sjögren's
por: Li, Zi Ying, et al.
Publicado: (2019)

Updates on the diagnosis and management of multicentric Castleman disease
por: Wu, Ya-Ju, et al.
Publicado: (2020)

Multicentric Castleman disease with infiltration of eosinophils to the lung
por: Nakai, Shogo, et al.
Publicado: (2021)

Candidate biomarkers for idiopathic multicentric Castleman disease
por: Sumiyoshi, Remi, et al.
Publicado: (2022)

Alveolar Hemorrhage in Idiopathic Multicentric Castleman’s Disease
por: Huang, Lingtong, et al.
Publicado: (2023)

PReS-FINAL-2198: Insufficient efficacy of tocilizumab therapy in children with Castleman's disease
por: Kozlova, A, et al.
Publicado: (2013)

Interleukin-6-producing Intravascular Large B-cell Lymphoma with Lymphadenopathy Mimicking the Histology of Multicentric Castleman Disease
por: Shiroshita, Kohei, et al.
Publicado: (2020)

TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy
por: Williams, Corinne, et al.
Publicado: (2021)

Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease: Study protocol for clinical trial
por: Koga, Tomohiro, et al.
Publicado: (2020)

The Potential Clinical Benefit of Tocilizumab Therapy for Patients with HHV-8-infected AIDS-related Multicentric Castleman Disease: A Case Report and Literature Review
por: Barlingay, Gauri, et al.
Publicado: (2020)

Reversed whole PTH/intact PTH ratio as an indicator of marked parathyroid enlargement: five case studies and a literature review
por: Komaba, Hirotaka, et al.
Publicado: (2008)

Radiological and Pathological Features of Cyst Formation in Idiopathic Multicentric Castleman Disease
por: Otoshi, Ryota, et al.
Publicado: (2023)

Irreversible Kidney Damage due to Multicentric Castleman's Disease
por: Kahn, Fredrik, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_qf895fsfh9t3ob3tejg62pdgup